Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data
Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…
Certara2026 年 1 月 13 日
Add Off-target Risk Profiling to Your Analyses
Certara's cheminformatics solution, D360, supports a key feature of Secondary Intelligence: a low-medium-high ranking of…
Certara2026 年 1 月 5 日
A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection
This study synthesizes data from a large body of clinical trials to evaluate rates of…
Certara2025 年 12 月 18 日
Merck Advances Pediatric Oncology with Innovative ADC Modeling
Merck leveraged ADC modeling and pediatric ADC dose optimization to enable FDA acceptance and advance…
Certara2025 年 12 月 12 日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
Certara2025 年 11 月 10 日
In silico Safety and Toxicology assessment: ToxStudio®
Discover how Certara’s ToxStudio align with FDA’s roadmap to reduce animal testing and transform preclinical…
Certara2025 年 10 月 30 日
AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success
Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…
Certara2025 年 10 月 21 日
Get clear, practical answers to the top 5 safety reporting questions & learn how to…
Certara2025 年 10 月 7 日
C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions
Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…
Certara2025 年 10 月 3 日
